Icatibant Universal Farma

Icatibant, the active ingredient in Icatibant Universal Farma, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection use. It treats hereditary angioedema in patients with C1‑inhibitor deficiency, reducing swelling episodes caused by excess bradykinin.

GNH USA supplies Icatibant Universal Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage hereditary angioedema, a disorder involving excessive bradykinin activity.

- Hereditary angioedema (type I & II, C1‑inhibitor deficiency): Reduces the frequency and severity of swelling attacks by blocking the B2 receptor. - Hereditary angioedema (type III, normal C1‑inhibitor): Provides rapid relief of acute edema through bradykinin antagonism. - Acute attacks of hereditary angioedema: Offers prompt symptom control when administered at the onset of swelling.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin flushing. - Swelling at injection site: transient localized edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Urticaria: widespread hives. - Angioedema unrelated to HAE: unexpected swelling in other areas. - Thrombocytopenia: low platelet count observed in rare cases. - Severe allergic reaction: includes bronchospasm or facial swelling.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: exercise caution; monitor renal function as clearance may be affected. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced angioedema. - Hypersensitivity: discontinue immediately if signs of severe allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or fluid balance.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may worsen angioedema. - Other bradykinin‑targeting biologics: may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of swelling or gastrointestinal irritation. - Estrogen‑containing contraceptives: can exacerbate hereditary angioedema attacks. - Diuretics: may alter fluid status and affect edema management.